• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percent of FDA advisory committee member positions vacant at the end of the month

Dictionary: Access to state-of-the-art, scientific expert advice to support agency decision making processes is imperative to the FDA advisory committee process. Having the fewest vacancies on our committees allows the agency to have ready access to those experts and supports the ability of FDA to meet its public health mission. For more information about FDA advisory committees, please visit http://www.fda.gov/AdvisoryCommittees/default.htm

Information is current as of March 31, 2014.

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetPercent Vacant Positions
Oct 20101025
Nov 20101023
Dec 20101023
Jan 20111025
Feb 20111023
Mar 20111023
Apr 20111022
May 20111020
Jun 20111020
Jul 20111023
Aug 20111021
Sep 20111020

Number of FDA advisory committee member positions vacant at the end of the month

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetVacant Positions
Oct 2010N/A155
Nov 2010N/A141
Dec 2010N/A140
Jan 2011N/A151
Feb 2011N/A139
Mar 2011N/A138
Apr 2011N/A133
May 2011N/A121
Jun 2011N/A120
Jul 2011N/A139
Aug 2011N/A130
Sep 2011N/A124

Total number of FDA advisory committee member positions at the end of the month

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetPositions
Oct 2010N/A608
Nov 2010N/A608
Dec 2010N/A608
Jan 2011N/A608
Feb 2011N/A608
Mar 2011N/A608
Apr 2011N/A608
May 2011N/A608
Jun 2011N/A608
Jul 2011N/A608
Aug 2011N/A621
Sep 2011N/A621

Footnotes

  • CVM's Advisory Committee was terminated on September 30, 2013.

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.